Follow-up evaluations for Ama and placebo group
| Baseline | 15 days | 30 days | Before withdrawal 60–240 days | 1 week after withdrawal | 1 month after withdrawal | ||
|---|---|---|---|---|---|---|---|
| The patients who withdrew because of side effects other than dyskinesia, (shown in the figure) are omitted from calculations. (Ama, n = 17; placebo, n = 18) | |||||||
| Values are mean (SD). | |||||||
| AMA | |||||||
| “On” time (hours) | 8.9 (2.4) | 9.6 (2.1) | 9.9 (1.9) | 9.0 (2.3) | 9.4 (2.0) | 9.1 (2.3) | |
| “Off” time (hours) | 6.4 (2.9) | 5.6 (2.5) | 4.8 (2.0) | 6.1 (2.4) | 6.2 (2.1) | 6.9 (2.3) | |
| UPDRS I–III | 52.9 (8.5) | 48.1 (7.8) | 47.2 (7.7) | 49.7 (7.9) | 51.1 (8.8) | 51.5 (9.2) | |
| UPDRS IV 32–34 | 6.7 (2.8) | 2.0 (1.1) | 2.3 (1.0) | 6.1 (2.8) | 7.0 (2.9) | 6.8 (2.9) | |
| IGA | reduction % | − | 100 | 100 | 0 | 0 | 58 |
| unchanged % | − | 0 | 0 | 6 | 35 | 35 | |
| increase % | − | 0 | 0 | 94 | 65 | 7 | |
| DRS | 19.6 (1.2) | 10.5 (1.3) | 10.3 (1.6) | 18.4 (1.5) | 22.2 (3.4) | 20.4 (1.4) | |
| PLACEBO | |||||||
| “On” time (hours) | 9.1 (2.1) | 9.2 (2.0) | 9.1 (2.2) | 9.0 (1.9) | 9.0 (2.1) | 9.0 (1.8) | |
| “Off” time (hours) | 6.2 (2.4) | 6.1 (2.1) | 6.2 (2.2) | 6.3 (2.1) | 6.3 (2.3) | 6.3 (2.2) | |
| UPDRS I–III | 52.7 (8.2) | 52.5 (8.3) | 52.7 (8.2) | 52.8 (8.1) | 52.8 (8.2) | 52.4 (8.0) | |
| UPDRS IV 32–34 | 6.6 (2.6) | 6.1 (2.4) | 6.4 (2.6) | 6.7 (2.6) | 6.8 (2.4) | 6.8 (2.3) | |
| IGA | reduction % | − | 11 | 11 | 0 | 0 | 28 |
| unchanged % | − | 83 | 61 | 61 | 72 | 61 | |
| increase % | − | 6 | 28 | 39 | 28 | 11 | |
| DRS | 20.4 (1.9) | 20.2 (1.6) | 20.0 (1.6) | 20.2 (1.5) | 20.4 (1.7) | 20.9 (1.7) | |